Phytohealth Corporation · TWSE:4108
Phytohealth — 2025 Institutional Investor Conference
26 slides from Phytohealth's conference presentation, Sep 2, 2025
Slide 1: Phytohealth Corporation
Phytohealth Corporation Taiwan Stock Exchange (symbol:4108) 2025 Institutional Investor Conference Established: 1998 Stock Exchange Listed: 2008 Capitalization: USD 70M Chairperson: Yili Lee CEO Angel Lee
Slide 2: Statement
Statement 1.Apart from historical data, the matters listed in this presentation that are forward-looking statements may be subject to significant risks and uncertainties, which could result in differences between these forward-looking statements and actual outcomes. 2.The future projections presente
Slide 3: Company Profile
Company Profile i T_T 7, RRR DAD PhytoHealth Corporation
Slide 4: PhytoHealth aims to apply the latest pharmaceutical drug development techniques
PhytoHealth aims to apply the latest pharmaceutical drug development techniques to innovate natural treatments used for thousands of years in Chinese botanical medicine practices to satisfy the unmet clinical needs.
Slide 5: Key milestones of Phytohealth Corporation
Key milestones of Phytohealth Corporation Company 1998 established 2002 Company public listing Listed on OTC as the first new drug R&D company 2008 • 1st botanical drug NDA • 1st oral nalbuphine received approval (PG2®) • API manufacturing factory NDA approval (Oraphine®) • Completion of Botanical a
Slide 6: Investigational new drugs
Phytohealth's new drug product development: 2 items have obtained TFDA drug licenses Product Function / Indication Pre-Clinical Phase I Phase II Phase III NDA Approval 懷特血寶® The world's only prescription drug to treat "Cancer Related Fatigue" Launched PG2 懷特痛寶® New analgesic (Nalbuphine) oral dosage
Slide 7: Global botanical and plant-derived drugs market
The global market for USD in 2024 botanical and plant-derived drugs has show continual growth over the last decade and is showing promise to continue moving forward at steady pace. USD by 2030 *Botanical and Plant-derived Drugs: Global CAGR Markets, BCC Research
Slide 8: Key factors holding back botanical drug markets
Key factors holding back botanical drug markets 1 Botanical Drug Guidance 2 Sufficient efficacy Key factors 3 Market traction
Slide 9: Our Track Record of Success
Our Track Record of Success Regulatory Evidence of Market Growth Approval Efficacy 1st New TFDA License 24 Research Articles PG2 is reimbursed by Taiwan For Prescription Botanical on PG2 found in top 25% National Health issuance. Drug issued by TFDA Leading Medical & Cancer the1st botanical drug (Ap
Slide 10: Sharing our Value Chain
Sharing our Value Chain R&D - Unmet Need in oncology, anti- COVID-19..etc Manufacturing PhytoHealth’s API Plant awarded with PIC/S RWE GMP Certificate - Data generation & Publication - CME program Sales & Marketing - Market Access strategy: self –pay & reimbursement - Focus on Hospital Channel - Pat
Slide 11: 2024-2025 key progress
2024-2025 key LT RETR DAD PhytoHealth Corporation
Slide 12: PG2 15 Years Post-Launch: Establishing a Strong Presence in Taiwan
1. PG2 15 Years Post-Launch: Establishing a Strong Presence in Taiwan, Accumulating Clinical Evidence, and Striving to Improve Cancer-Related Fatigue
Slide 13: 92% of patients have cancer-related fatigue
92% of patients have cancer-related fatigue According to the "Guidelines of Management of Cancer related Fatigue1” Astragals polysaccharide injection (PG2® ) is recommended to treat moderate to sever cancer related fatigue (Level 1A, Grade A Recommendation ) 1. Management of Cancer Related Fatigue i
Slide 14: 2025 PG2 15th Anniversary Symposium
2025 PG2 15th Anniversary Symposium — Sustaining Milestones and Exploring Future Perspectives
Slide 15: Expanding the Launch and Promotion of Oraphine Locally and Globally
2. Expanding the Launch and Promotion (Oraphine) ® Locally and Globally
Slide 16: Oraphine - A Novel Oral Analgesic
Oraphine ® - A Novel Oral Analgesic For Moderate to Severe Pain Management Source : Summarized by PHC team
Slide 17: Oraphine 60mg Soft Capsule: The Ideal Oral Opioid for Postoperative Pain Relief
Oraphine®60mg@soft Capsule : The Ideal Oral Opioid for Multimodal Acute Postoperative Pain Relief • Target Self-Paid Postoperative Pain Management Market : Obstetrics & Gynecology Orthopedics Neurosurgery • Expanding Adoption in Domestic Hospitals : Hualien Tzu Chi Hospital, Tri-Service General Hosp
Slide 18: Starting the product registration process for the German market launch
Starting the product registration process for the German market launch Founded in Germany in 2008, the company operates 5 production facilities, generates over USD 500 million in annual revenue, employs 1,780 people, and sells its products in 38 countries worldwide. Q1 2025: Sales cooperation LOI
Slide 19: Enter food supplement market with the spirit of new drug research
3. Enter food supplement market with the spirit of new drug research and development
Slide 20: Functional Foods Utilizing Patented Botanical Extraction Technology
Functional Foods Utilizing Patented Botanical Extraction Technology 20
Slide 21: Enhancing Brand Value and Fostering Business Partnerships
Enhancing Brand Value and Fostering Business Partnerships
Slide 22: Corporate Sustainability × Public Welfare Participation ESG
Annual Core Values Corporate Achievements Sustainability ×PublicWelfareParticipation Clinical Education ×Patient Care • Completed 2024 ESG report • Completed SASB Standard Disclosure ESG Driving Sustainable Health Value Creation • Completed Greenhouse Gas Inventory GRI Sustainability 1 Clinical Educ
Slide 23: Financial Information
Financial Information WT ¢, Bist ier AG) PhytoHealth Corporation
Slide 24: Balance Sheet
Sound financial structure 1. Sufficient cash 「Balance Sheet」 2. Low debts ratio (Expressed in Thousands of New Taiwan Dollars) Account 114.6.30 % 113.12.31 % CURRENT ASSETS 1,495,557 64 1,306,393 54 NON-CURRENT 842,571 36 1,133,277 46 TOTAL ASSETS 2,338,128 100 2,439,670 100 CURRENT LIABILITIES 40,0
Slide 25: Income statement
Net loss reduced by 17% compared with 「Income statement」 the same period last year (Expressed in Thousands of New Taiwan Dollars) 114年 1-6月 113年 1-6月 增減率% Account (A) % (B) % (A-B)/B Net Sales 61,570 100 76,713 100 (20) Gross Margin 19,563 32 30,161 39 (35) Operating Exp. (101,828) (165) (106,438) (
Slide 26: 26
26